CHARMD

Comprehensive Herpesviruses Antiviral drug Resistance Mutation Database


    • TOP

    Antiviral research


    Mutations:

    Mutant Gene Virus Reference
    R233S UL27 Human betaherpesvirus 5 Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus. (Sep 2018)
    A4T UL51 Human betaherpesvirus 5 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    D12E UL51 Human betaherpesvirus 5 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    G16A UL51 Human betaherpesvirus 5 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    E17A UL51 Human betaherpesvirus 5 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    E17del UL51 Human betaherpesvirus 5 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    Q23K UL51 Human betaherpesvirus 5 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    D24G UL51 Human betaherpesvirus 5 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    S28F UL51 Human betaherpesvirus 5 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    E39D UL51 Human betaherpesvirus 5 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    D40N UL51 Human betaherpesvirus 5 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    E42G UL51 Human betaherpesvirus 5 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    G56D UL51 Human betaherpesvirus 5 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    G61D UL51 Human betaherpesvirus 5 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    L70I UL51 Human betaherpesvirus 5 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    P91S UL51 Human betaherpesvirus 5 A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance. (Dec 2017)
    A95V UL51 Human betaherpesvirus 5 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    V113L UL51 Human betaherpesvirus 5 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    S153P UL51 Human betaherpesvirus 5 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    S290R UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    S290R UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    S290R UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    S290R UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    S290R UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    S290R UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    N408S UL54 Human betaherpesvirus 5 Novel DNA polymerase mutations conferring cytomegalovirus resistance: input of BAC-recombinant phenotyping and 3D model. (Apr 2013)
    N408S UL54 Human betaherpesvirus 5 Novel DNA polymerase mutations conferring cytomegalovirus resistance: input of BAC-recombinant phenotyping and 3D model. (Apr 2013)
    N408S UL54 Human betaherpesvirus 5 Novel DNA polymerase mutations conferring cytomegalovirus resistance: input of BAC-recombinant phenotyping and 3D model. (Apr 2013)
    K426E UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    K426E UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    K426E UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    K426E UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    K426E UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    K426E UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    A492D UL54 Human betaherpesvirus 5 Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance. (Jul 2016)
    A492D UL54 Human betaherpesvirus 5 Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance. (Jul 2016)
    A492D UL54 Human betaherpesvirus 5 Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance. (Jul 2016)
    N495K UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    N495K UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    N495K UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    N495K UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    N495K UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    N495K UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    N498S UL54 Human betaherpesvirus 5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    N498S UL54 Human betaherpesvirus 5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    N498S UL54 Human betaherpesvirus 5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    D515Y UL54 Human betaherpesvirus 5 Contrasting effect of new HCMV pUL54 mutations on antiviral drug susceptibility: Benefits and limits of 3D analysis. (May 2016)
    D515Y UL54 Human betaherpesvirus 5 Contrasting effect of new HCMV pUL54 mutations on antiviral drug susceptibility: Benefits and limits of 3D analysis. (May 2016)
    D515Y UL54 Human betaherpesvirus 5 Contrasting effect of new HCMV pUL54 mutations on antiviral drug susceptibility: Benefits and limits of 3D analysis. (May 2016)
    D515E UL54 Human betaherpesvirus 5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    D515E UL54 Human betaherpesvirus 5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    D515E UL54 Human betaherpesvirus 5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    L516W UL54 Human betaherpesvirus 5 Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance. (Jul 2016)
    L516W UL54 Human betaherpesvirus 5 Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance. (Jul 2016)
    L516W UL54 Human betaherpesvirus 5 Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance. (Jul 2016)
    C524del UL54 Human betaherpesvirus 5 Novel DNA polymerase mutations conferring cytomegalovirus resistance: input of BAC-recombinant phenotyping and 3D model. (Apr 2013)
    C524del UL54 Human betaherpesvirus 5 Novel DNA polymerase mutations conferring cytomegalovirus resistance: input of BAC-recombinant phenotyping and 3D model. (Apr 2013)
    C524del UL54 Human betaherpesvirus 5 Novel DNA polymerase mutations conferring cytomegalovirus resistance: input of BAC-recombinant phenotyping and 3D model. (Apr 2013)
    D542E UL54 Human betaherpesvirus 5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    D542E UL54 Human betaherpesvirus 5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    D542E UL54 Human betaherpesvirus 5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    A543V UL54 Human betaherpesvirus 5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    A543V UL54 Human betaherpesvirus 5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    A543V UL54 Human betaherpesvirus 5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    T552N UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    T552N UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    T552N UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    T552N UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    T552N UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    T552N UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    V715A UL54 Human betaherpesvirus 5 Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance. (Jul 2016)
    V715A UL54 Human betaherpesvirus 5 Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance. (Jul 2016)
    V715A UL54 Human betaherpesvirus 5 Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance. (Jul 2016)
    Q783R UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    Q783R UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    Q783R UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    Q783R UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    A786V UL54 Human betaherpesvirus 5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    A786V UL54 Human betaherpesvirus 5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    A786V UL54 Human betaherpesvirus 5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    V798A UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    V798A UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    V798A UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    V798A UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    V798A UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    A809V UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    A809V UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    A928T UL54 Human betaherpesvirus 5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    A928T UL54 Human betaherpesvirus 5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    A928T UL54 Human betaherpesvirus 5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    E949K UL54 Human betaherpesvirus 5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    E949K UL54 Human betaherpesvirus 5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    E949K UL54 Human betaherpesvirus 5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    E949Q UL54 Human betaherpesvirus 5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    E949Q UL54 Human betaherpesvirus 5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    E949Q UL54 Human betaherpesvirus 5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    E951D UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    E951D UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    E951D UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    E951D UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    E951D UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    E951D UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    A987G UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    A987G UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    D981del2 UL54 Human betaherpesvirus 5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    D981del2 UL54 Human betaherpesvirus 5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    D981del2 UL54 Human betaherpesvirus 5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    V33A UL56 Human betaherpesvirus 5 Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    A36V UL56 Human betaherpesvirus 5 Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    E75G UL56 Human betaherpesvirus 5 Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    L122P UL56 Human betaherpesvirus 5 Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    R129H UL56 Human betaherpesvirus 5 Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    A221V UL56 Human betaherpesvirus 5 Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    S229F UL56 Human betaherpesvirus 5 A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance. (Dec 2017)
    S229Y UL56 Human betaherpesvirus 5 Phenotypes of cytomegalovirus genetic variants encountered in a letermovir clinical trial illustrate the importance of genotyping validation. (Aug 2024)
    V231L UL56 Human betaherpesvirus 5 Phenotypes of cytomegalovirus genetic variants encountered in a letermovir clinical trial illustrate the importance of genotyping validation. (Aug 2024)
    V231L UL56 Human betaherpesvirus 5 Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
    Q234R UL56 Human betaherpesvirus 5 Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
    V236M UL56 Human betaherpesvirus 5 Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus. (Sep 2018)
    L243P UL56 Human betaherpesvirus 5 Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
    L254F UL56 Human betaherpesvirus 5 A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance. (Dec 2017)
    L257F UL56 Human betaherpesvirus 5 A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance. (Dec 2017)
    S262C UL56 Human betaherpesvirus 5 Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
    L328I UL56 Human betaherpesvirus 5 Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
    M329I UL56 Human betaherpesvirus 5 Phenotypes of cytomegalovirus genetic variants encountered in a letermovir clinical trial illustrate the importance of genotyping validation. (Aug 2024)
    H335Y UL56 Human betaherpesvirus 5 Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
    E339G UL56 Human betaherpesvirus 5 Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
    K350R UL56 Human betaherpesvirus 5 Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
    V363I UL56 Human betaherpesvirus 5 Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
    N368D UL56 Human betaherpesvirus 5 A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance. (Dec 2017)
    N368I UL56 Human betaherpesvirus 5 Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
    R369K UL56 Human betaherpesvirus 5 Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
    T399I UL56 Human betaherpesvirus 5 Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
    N446S UL56 Human betaherpesvirus 5 Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    450-453del UL56 Human betaherpesvirus 5 Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    A464V UL56 Human betaherpesvirus 5 Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    H509N UL56 Human betaherpesvirus 5 Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    V582M UL56 Human betaherpesvirus 5 Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    G649D UL56 Human betaherpesvirus 5 Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    H698Q UL56 Human betaherpesvirus 5 Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    C721Y UL56 Human betaherpesvirus 5 Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    A779T UL56 Human betaherpesvirus 5 Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    A779V UL56 Human betaherpesvirus 5 Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    A788T UL56 Human betaherpesvirus 5 Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    V793P UL56 Human betaherpesvirus 5 Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    Y806T UL56 Human betaherpesvirus 5 Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    T811P UL56 Human betaherpesvirus 5 Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    A812G UL56 Human betaherpesvirus 5 Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    G813A UL56 Human betaherpesvirus 5 Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    A820Q UL56 Human betaherpesvirus 5 Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    L38M UL89 Human betaherpesvirus 5 Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    D344E UL89 Human betaherpesvirus 5 Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus. (Sep 2018)
    M359I UL89 Human betaherpesvirus 5 Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
    L562F UL89 Human betaherpesvirus 5 Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    A659V UL89 Human betaherpesvirus 5 Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    V673I UL89 Human betaherpesvirus 5 Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    S7F UL97 Human betaherpesvirus 5 Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavir. (Jul 2011)
    L14F UL97 Human betaherpesvirus 5 Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavir. (Jul 2011)
    R112H UL97 Human betaherpesvirus 5 Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavir. (Jul 2011)
    R112C UL97 Human betaherpesvirus 5 A new tool linking human cytomegalovirus drug resistance mutations to resistance phenotypes. (Feb 2010)
    P132L UL97 Human betaherpesvirus 5 Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavir. (Jul 2011)
    S133P UL97 Human betaherpesvirus 5 Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavir. (Jul 2011)
    V171I UL97 Human betaherpesvirus 5 Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavir. (Jul 2011)
    A238T UL97 Human betaherpesvirus 5 Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavir. (Jul 2011)
    S249C UL97 Human betaherpesvirus 5 Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavir. (Jul 2011)
    Y335H UL97 Human betaherpesvirus 5 Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
    Y335H UL97 Human betaherpesvirus 5 Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
    L337M UL97 Human betaherpesvirus 5 Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo. (Aug 2012)
    L337M UL97 Human betaherpesvirus 5 Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo. (Aug 2012)
    F342Y UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    F342Y UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    F342Y UL97 Human betaherpesvirus 5 Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
    F342Y UL97 Human betaherpesvirus 5 Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
    V345I UL97 Human betaherpesvirus 5 Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
    V345I UL97 Human betaherpesvirus 5 Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
    L348V UL97 Human betaherpesvirus 5 Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
    L348V UL97 Human betaherpesvirus 5 Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
    K359E UL97 Human betaherpesvirus 5 Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection. (Dec 2019)
    K359Q UL97 Human betaherpesvirus 5 Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection. (Dec 2019)
    E362D UL97 Human betaherpesvirus 5 Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
    E362D UL97 Human betaherpesvirus 5 Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
    V388M UL97 Human betaherpesvirus 5 Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
    V388M UL97 Human betaherpesvirus 5 Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
    L397R UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    L397R UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    T409M UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    T409M UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    H411Y UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    H411Y UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    H415Y UL97 Human betaherpesvirus 5 Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
    H415Y UL97 Human betaherpesvirus 5 Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
    A435V UL97 Human betaherpesvirus 5 Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
    A435V UL97 Human betaherpesvirus 5 Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
    C437Y UL97 Human betaherpesvirus 5 Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
    C437Y UL97 Human betaherpesvirus 5 Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
    Q449R UL97 Human betaherpesvirus 5 Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavir. (Jul 2011)
    M460I UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    M460I UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    M460V UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    M460V UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    C480F UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    C480F UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    H520Q UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    H520Q UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    C592G UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    C592G UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    C592G UL97 Human betaherpesvirus 5 Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
    C592G UL97 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    C592G UL97 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    A594P UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    A594P UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    A594V UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    A594V UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    A594S UL97 Human betaherpesvirus 5 Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
    A594V UL97 Human betaherpesvirus 5 Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
    L595F UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    L595F UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    L595S UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    L595S UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    L595W UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    L595W UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    L595S UL97 Human betaherpesvirus 5 Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
    N597del UL97 Human betaherpesvirus 5 Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
    597-598del UL97 Human betaherpesvirus 5 Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
    597-599del UL97 Human betaherpesvirus 5 Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
    K599R UL97 Human betaherpesvirus 5 Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
    599-603del UL97 Human betaherpesvirus 5 Genetic analysis of a ganciclovir-resistant human cytomegalovirus mutant. (Dec 1998)
    K599T UL97 Human betaherpesvirus 5 Genetic analysis of a ganciclovir-resistant human cytomegalovirus mutant. (Dec 1998)
    L600I UL97 Human betaherpesvirus 5 Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
    T601M UL97 Human betaherpesvirus 5 Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
    C603W UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    C603W UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    C603Y UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    C603Y UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    C603W UL97 Human betaherpesvirus 5 Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
    D605E UL97 Human betaherpesvirus 5 Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
    A613V UL97 Human betaherpesvirus 5 Generation and characterization of a GCV resistant HCMV UL97-mutation and a drug sensitive UL54-mutation. (Dec 2013)
    M615V UL97 Human betaherpesvirus 5 Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavir. (Jul 2011)

    Tilloy et al., 2024
    Interdeposit Digital Number: IDDN.FR.001.420004.000.S.X.2024.000.31230